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AIMS
Inappropriate use of antibiotics is one of the most important factors contributing to the emergence of drug resistant pathogens.
The purpose of this study was to measure the clinical impact of antimicrobial stewardship programme (ASP) interventions on
hospitalized patients at the Intensive care unit at Palestinian Medical Complex.
METHODS
A prospective audit with intervention and feedback by ASP team within 48–72 h of antibiotic administration began in September
2015. Four months of pre-ASP data were compared with 4 months of post-ASP data. Data collected included clinical and de-
mographic data; use of antimicrobials measured by deﬁned daily doses, duration of therapy, length of stay, readmission and all-
cause mortality.
RESULTS
Overall, 176 interventions were made the ASP team with an average acceptance rate of 78.4%. The most accepted interventions
were dose optimization (87.0%) followed by de-escalation based on culture results with an acceptance rate of 84.4%. ASP in-
terventions signiﬁcantly reduces antimicrobial use by 24.3% (87.3 deﬁned daily doses/100 beds vs. 66.1 deﬁned daily doses/100
beds P < 0.001). The median (interquartile range) of length of stay was signiﬁcantly reduced post ASP [11 (3–21) vs. 7 (4–19)
days; P< 0.01]. Also, the median (interquartile range) of duration of therapy was signiﬁcantly reduced post-ASP [8 (5–12) days vs.
5 (3–9); P = 0.01]. There was no signiﬁcant difference in overall 30-day mortality or readmission between the pre-ASP and post-
ASP groups (26.9% vs. 23.9%; P = 0.1) and (26.1% vs. 24.6%; P = 0.54) respectively.
CONCLUSIONS
Our prospective audit and feedback programme was associated with positive impact on antimicrobial use, duration of therapy
and length of stay.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Inappropriate use of antibiotic has been associated with increased resistance, morbidity and hospital stay.
• Antimicrobial stewardship programmes (ASPs) aim to improve patient safety and outcomes whilst reducing adverse ef-
fects associated with antimicrobial use
WHAT THIS STUDY ADDS
• This study identiﬁed the current patterns of antibiotic prescribing and the impact of an ASP on these practices.
• ASP interventions are effective to manage the antimicrobial prescription according the local guidelines
• The ASP team can effectively participate in health education to promote the rational use of antimicrobial agents
Introduction
Much has been written about antimicrobial resistance (AR) as
an important factor in both patient-safety and public-health
[1]. Reports of AR bacterial infections are growing, and the
ability of pharmaceutical industry to generate new classes of
antibiotics is limited [2, 3]. Factors that are known to contrib-
ute to AR include the extent of antimicrobial exposure and
consumption of antibiotics in a population [4–7]. A recent
meta-analysis demonstrated a link between primary care phy-
sicians prescribing of antibiotics to AR in pathogens causing
respiratory, urinary and skin infections [6].
The search for a way to improve antimicrobial prescribing
practices has been addressed by the implementation of anti-
microbial stewardship programmes (ASP) to control AR [7].
ASP includes measures to promote the appropriate use of an-
timicrobials. Such measures include: educational
programmes for all clinical staff to ensure competency;
evidence-based optimal treatment for routine infections;
communication of issues related to antimicrobial use to
stakeholders; and ﬁnally monitor the impact on change in
clinical practice [8–11]. Ultimately, the aims of ASP are to im-
prove efﬁcacy, minimize adverse effects and limit AR. Infec-
tions caused by susceptible organisms are easier to treat
than those caused by resistant organisms that may have poor
clinical outcome (morbidity and mortality), extended hospi-
tal stay and higher cost [12].
Two core ASP strategies have been adopted by the Infec-
tious Diseases Society of America to reduce the inappropriate
use of antimicrobials: prospective audit and feedback inter-
ventions [11, 13]. The main attribute of prospective audit
and feedback strategy is that acceptance of recommendations
is voluntary; as such doctors maintain their prescribing au-
tonomy [14]. It is therefore more acceptable to doctors and
less likely to be opposed. In fact, due to the feedback mecha-
nism, this type of intervention may be considered
educational.
Another point to consider is the method for implementa-
tion and evaluation of such programmes. Some of the options
include; the selection of audit cases based on surgical or
medical ﬁelds and/or based on pre-deﬁned antibiotics.
Monitoring for consumption can be done in the form of
deﬁned daily doses (DDD) or days of therapy [15, 16]. This
may identify high prescription areas and maximize the
impact of interventions.
To date, there has been no programme or evaluation of
ASP in Palestinian hospitals. Hence, in this study, the aim
is to evaluate the impact of ASP on the following out-
comes: (i) antibiotic consumption; (ii) duration of therapy;
(iii) length of hospital stay; (iv) intervention acceptance
rate; (v) readmission within 30 days of discharge; and (vi)
mortality within 30 days of ASP audit.
Methodology
Patients and setting
This was a single-centre, prospective, pre- and postinterven-
tion study at Palestinian Medical Complex (PMC) in
Ramallah. The PMC consists of ﬁve hospitals; Ramallah
Public Hospital; Al-Sheikh Zayed Hospital; National Center
for Blood Diseases; Bahrain Pediatrics Hospital; and Kuwaiti
Specialized Surgery Hospital. The PMC has 214 beds. It
provides a wide range of services, including neonatal care,
maternity care, internal medicine, paediatrics, general
surgery and cardiovascular surgery.
All patients admitted to the intensive care unit (ICU) and
administered any antimicrobial drug were included in the
study. A review of the ASP database was conducted, for inter-
ventionsmade between September 2015 andDecember 2015.
Description of the ASP
The ASP team, consisting of an infectious diseases physician,
clinical microbiologist, clinical pharmacists at the 12-bed
ICU, drew up new antibiotic guidelines for empirical treat-
ment of common infections. Evidence for these guidelines
was drawn from international published guidelines and was
adapted to Palestinian Medical complex microbial suscepti-
bility patterns. The clinical pharmacists performed the
primary review, screened cases for appropriateness and made
therapeutic recommendations; for example, dosage optimi-
zation, or switch from intravenous to oral antibiotics. These
recommendations were reviewed by the ASP team on the
2nd, 4th and 7th days, allowing for bacterial culture to be
processed with recommendations for de-escalation, change,
dose adjustment of antibiotics where appropriate (Figure 1).
Criteria used to determine if antimicrobial was inappropri-
ately prescribed include:
• If hospital antibiotic guidelines were not followed without
reasonable explanation;
• If empiric treatment was less than optimal per guideline
including dose level, dose duration or dosing regimen;
• If cultures results indicate that a narrower-spectrum antibi-
otic may be more appropriate;
• If culture results show that there was no infection and an
alternative reason for the fever is identiﬁed.
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The prospective audit with intervention and feedback
made by the ASP team within 48–72 h of antibiotic adminis-
tration began in September 2015. Four months of pre-ASP
data were compared with 4 months of post-ASP data. Data
collected included clinical and demographic data; as well as
use of antimicrobials which was calculated using DDD.
Data collections and outcomes
Compliance with or rejection of ASP recommendations was
determined via review of patient’s medical record/chart at
24 and 48 h after antibiotic recommendation. During the
study period, hospital pharmacy records were used to obtain
drug prescription data for the audited antibiotics. DDD/100
beds for each drug or drug category prescribed monthly were
calculated following theWorld Health Organization Anatom-
ical Therapeutic Chemical classiﬁcation system [17]. All
recommendations made by ASP team were recorded on a
standardized form.
Ethics
The study was approved by PalestinianMedical Complex eth-
ical committee. Informed consent was deemed unnecessary
since ASP constituted routine clinical practice andmedical re-
cord analysis was analysed anonymously.
Data analysis
All statistical calculations were analysed using SPSS version
16.0 (SPSS Inc., Chicago, IL). Data were expressed as the
mean ± standard deviation for continuous variables, and un-
paired Student t test was performed to determine differences
betweenmean values. For noncontinuous variables data were
expressed as median [interquartile range (IQR)].
Mann–Whitney test was performed; for categorical variables,
data were expressed as number and percentage and were
analysed by chi-square test or Fisher exact test, as appropriate.
Results
Demographics and comorbid conditions
There were no statistically signiﬁcant differences in terms of
age, number of comorbid conditions, previous hospitaliza-
tion and previous antibiotic use between the pre-ASP group
and post-ASP group (Table 1). Patients in the post-ASP period
had more episodes of sepsis and respiratory infections. Types
of infection were deﬁned based on the International Classiﬁ-
cation ICD-10 [17].
Interventions
During the post-ASP period, a total of 356 antimicrobial pre-
scriptions for 142 patients were revised during a 4-month pe-
riod. Of these, 49.4% were considered inappropriate in 101
patients. The majority of interventions recommended by
ASP team were: de-escalating 64 (36.4%); discontinue antibi-
otics 53 (30.1%); and intravenous to oral switch intervention
32 (18.2%). Overall, 176 interventions were made by ASP
team with an average acceptance rate of 78.4% by the ICU
team. The most accepted interventions were dose optimiza-
tion based on pharmacokinetic and dynamics of antibiotics
with an acceptance rate of 87.0% followed by de-escalation
based on culture results with an acceptance rate of 84.4%
(Table 2). Changing the antibiotic was the most common rea-
son for non-acceptance, another key reasonwas the ICU team
did not view the recommendations; therefore, the recom-
mendations were no longer applicable.
Figure 1
Schematic diagram of the antimicrobial stewardship programme prospective audit with immediate concurrent feedback workﬂow
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Antibiotic use
There were seven drugs in the drug use 90% segment selected
for audit out of 21 drugs prescribed in the ICU (Figure 2).
Overall utilization was reduced by 24.3% (87.3 DDD/100
beds vs. 66.1 DDD/100 beds; P < 0.001), speciﬁcally driven
by third generation cephalosporins, carbapenems and
ﬂuroquinolones. Ceftriaxone use was reduced by 34.2%
(18.4 DDD/100 beds vs. 12.1 DDD/100 beds; P < 0001),
piperacillin/tazobactam use decreased by 17.7% (12.4
DDD/100 beds vs. 10.2 DDD/100 beds; P < 0.001), and
meropenem use decreased by 22.2 (10.8 DDD/100 vs. 8.4
DDD/100 beds; P < 0.001).
Clinical outcomes
The median (IQR) lengths of hospital stay before and after
implementation of the ASP were 11 (3–21) days and 7 (4–19)
days, respectively (P < 0.01). Also, there was a statistically
signiﬁcant difference in duration of therapy between the
median (IQR) of pre-ASP group [8 (5–12) days] and the post-
Table 1
Patient demographics and comorbid conditions by period
Demographic characteristics Pre-ASP period (n = 115) Post-ASP period (n = 142) P
Mean age (years) 68.4 (15.3) 70.1 (16.6) 0.35
Male sex 55 (47.8) 82 (57.7) 0.01
Previous hospitalization within 3 months 53 (46.1) 68 (47.9) 0.43
Previous antibiotic use within 3 months 79 (68.7) 90 (63.4) 0.17
Comorbid conditions <0.01
No comorbidities 9 (7.8) 21 (14.8)
1–2 47 (40.8) 65 (45.8)
3–4 43 (37.4) 44 (30.9)
>5 16 (14.0) 12 (8.5)
Median (IQR) 4 (0–13) 4 (0–12)
Respiratory infection 44 (38.3) 62 (43.7) <0.01
Sepsis 27 (23.5) 29 (20.4) <0.01
Genitourinary 10 (8.7) 19 (13.4) <0.01
Skin, joint bone, soft tissue 11 (9.6) 14(9.9) 0.88
Infection of the central nervous system 9 (7.8) 10 (7.0) 0.68
Infection of cardiovascular system 4 (3.5) 6 (4.2) 0.28
Others 10 (8.6) 2 (1.4) <0.01
Data are mean ± standard deviation, median (interquartile range, IQR), or number (%) of patients
Differences assessed by Fisher’s exact or χ2 test (categorical data), t test (continuous data) as appropriate
ASP, antimicrobial stewardship programme
Table 2
Types of interventions recommended by the antimicrobial stewardship programme team
Intervention n (%) Accepted, n (%)
De-escalation based on culture results 64 (36.4) 54 (84.4)
Discontinue antibiotic 53 (30.1) 41 (77.4)
Dose optimization 23 (13.1) 20 (87.0)
Intravenous-to-oral switch 32 (18.2) 21 (65.6)
Adding an antibiotic 4 (2.3) 2 (50.0)
Total 176 (100) 138 (78.4)
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ASP group [5 (3–9) days; P = 0.01]. There was no signiﬁcant
difference in overall mortality between the pre-ASP group
(31, 26.9%) and the post-ASP group (34, 23.9%; P = 0.1).
Regarding readmission, independent samples t test
showed no signiﬁcant differences between pre- and post-ASP
(Table 3). Of the 84 surviving patients in the pre-ASP group 30
(26.1%) were re-admitted within 30 days of discharge and 17
(14.8%) were re-admitted within 60 days of discharge. Of the
108 surviving patients in the post-ASP, 35 (24.6%) were re-
admitted within 30 days and 18 (12.7%) within 60 days of
discharge (P = 0.54, P = 0.28 respectively).
Discussion
Little is known about the impact of implementing an ASP and
monitoring of antimicrobial prescribing in Palestinian hospi-
tals. Moreover, most drug related problems in hospitals are
caused by anti-infective medications [18]. To the best of our
knowledge this study was the ﬁrst in West Bank to focus on
the clinical impact of implementing ASP on patient clinical
outcomes. One important core strategy of ASP, the prospec-
tive audit and feedback strategy will probably be the most
widely implemented in view of its clear advantages particu-
larly with regards to lack of opposition from prescribers [19].
One of the desirable targets of an ASP is to control
inappropriate and overuse of broad spectrum antibiotics. It
is estimated that 50% of antimicrobial use in hospitals is
inappropriate [20]; our study conﬁrms this number since
49.4% of antibiotic prescriptions were deemed to require
intervention.
Consumption of restricted antibiotics was signiﬁcantly
reduced after implementation of ASP. Previous studies have
shown that ASPs have consistently been effective in reducing
prescriptions of restricted antibiotics [21–24]. Our study
showed that consumption of all seven audited antimicrobials
decreased due to ASP intervention. Ceftriaxone consumption
was noticeably high at baseline and ASP intervention resulted
in a signiﬁcant decrease in its use. This may be attributed to
the fact that approximately 40% of patients in the study
suffered from respiratory diseases and chest infections. Based
on local and international management standards on
pneumonia, it is likely that the empirical therapy doctors
selected was a cephalosporin [25, 26]. Other broad-spectrum
antibiotics that had signiﬁcant reductions in consumption
include ﬂuoroquinolones and carbapenems. Out of the ﬁve
interventions evaluated in this study, de-escalation of
antibiotic based on culture results antibiotic were the most
commonly encountered, if no resistant organism (e.g.
Pseudomonas aeruginosa, Acinetobacter spp. or methicillin-
resistant Staphylococcus aureus).
It was observed from this study that the ICU physicians
were more likely to accept ASP interventions; however, ap-
proximately 22% of the ASP interventions were rejected by
the physicians. The main reason for rejection is changing
the antibiotic. This may be expected considering that many
physicians have personal preferences with no clear reasons
indicated. Another possible reason for rejection of the
recommendation may be the fact that some of the cases de-
veloped complications. In such situations, physicians may
opt to be cautious and reject ASP interventions that may
deviate from their opinions. Moreover, physicians are not
Figure 2
Antimicrobial use pre- and post-antimicrobial stewardship pro-
gramme intervention
Table 3
Outcomes: post-antimicrobial stewardship programme (ASP) period compared with pre-ASP period
Outcome Pre-ASP period (n = 115) After-ASP period (n = 142) P-Value
Duration of therapy (days), median (IQR)a 8 (5–12) 5 (3–9) 0.01*
Length of stay (days), median (IQR)a 11 (3–21) 7 (4–19) 0.01*
30-day readmissionb 30 (26.1) 35 (24.6) 0.54
60-day readmissionb 17 (14.8) 18 (12.7) 0.28
30-day all-cause mortalityb 31 (26.9) 34 (23.9) 0.10
aMann–Whitney U test,
bStudent t test,
*signiﬁcant P < 0.05
IQR, interquartile range
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keen to change antibiotics despite microbiology results sug-
gesting that narrower-spectrum antibiotics can be pre-
scribed, as the patients had responded to the initial
empiric antibiotics.
It should be noted that our recommendations were made
through written notes. On some occasions, the ICU team did
not view the recommendations within the speciﬁed 48 h;
therefore, the recommendations were no longer applicable
and were considered a rejection. One consideration may be
that direct face-to-face communication with the providers
may have had a greater impact or acceptance. One of the
more common interventions made by ASP was to switch to
oral therapy intervention, which has two main beneﬁts: ﬁrst,
it reduces the cost of treatment for the patients as it is less
expensive than parenteral antibiotic; second, it has fewer
incidences of catheter-related infections and may lead to a
shorter hospital stay.
A decrease in both length of hospital stay and duration of
therapy after implementation of the ASP was observed. How-
ever, the relationship between the decrease in hospital stay
and the decrease in antimicrobial consumption is not clear.
The study cannot distinguish if the decrease in antimicrobial
consumption is caused by the shorter hospital stay or if ASP
intervention resulted in better treatment and shorter hospi-
talization duration or duration of therapy. Many ASP studies
have shown a reduction in hospital stay [27]. Many potential
confounders affect the overall hospital stay and it is difﬁcult
to determine the impact of ASP precisely. Future research
needs to focus on hospital stay as it appears to be an impor-
tant measure of the impact of an ASP.
Regarding mortality and re-admissions, our ﬁndings are
similar to most studies, which have demonstrated little to
no impact of prospective audit and feedback ASPs on mortal-
ity [28–30] and 30-day readmission [29, 31]. This may be
because of the large number of factors that may affect clinical
response and outcomes. As ASPs continue to evolve, they
may include some of the confounding factors such as resis-
tance rate, drug costs, and total costs of care. Addition of
those factors may allow for better characterization of the rela-
tionship between ASP and mortality and/or re-admissions.
The results of our study are in line with other
programmes that studied the impact of ASP in critical care
and showed that ASP interventions were associated with
shorter duration of antibiotic therapy, less inappropriate
antimicrobial use [32].
In general, ASPs studies have consistently shown a reduc-
tion in the average length of hospital stay, infection-related
re-admissions and 14-day re-infection rate. By contrast,
assessment of 30-day mortality has shown little or no differ-
ence [33]. The reason for such observation appears to be that
many factors affect mortality (and length of hospitalization)
while the effect of intervention by antimicrobial stewardship
(i.e. shortened duration of therapy or choice of a narrower-
spectrum antibiotic) appears negligible.
This study showed that ASP can be introduced success-
fully into hospitals in low- andmiddle-income countries with
limited human resources, which never practiced stewardship
before [34, 35]. Pharmacists would need to be trained inmon-
itoring antibiotic use, and would be allowed time in partner-
ship with other healthcare professionals according to the
size of hospital [36].
The prospective audit and feedback methodology allows
for a team-based approach to patient care with a focus on
both individual patient outcomes and global hospital out-
comes. Here, practitioners initiate therapy, and the ASP team
intervenes only in select cases. These programmes address
both over- and under-treatment. This method allows the
ASP team to interact directly with prescribers to tailor speciﬁc
antibiotic therapy for each patient.
Practitioners may be more receptive to the stewardship
programme when suggestions are not only limited to a reduc-
tion of antibiotic usage but are also focused on optimal pa-
tient care [37].
Implementation of an ASP in a Palestinian hospital over a
relatively short time achieved results that appear consistent
with other publications in this ﬁeld of science [33–36]. This
ﬁnding is particularly interesting, considering that most hos-
pitals do not have a clinical pharmacist with formal training
in infectious diseases to provide antimicrobial consultation.
Other practices that may improve antimicrobial use may in-
clude: implementation of antimicrobial guide with empiric
treatment recommendations. Certainly, the addition of rou-
tine education programmes for health care professional may
improve overall antimicrobial use and provide update on
new treatment options.
Limitations
There are several limitations to our study. The study design
pre- and postintervention is associated with a number of
inherent limitations, including the potential for confound-
ing bias.
The ASP study duration was 4 months; it is possible
that this study duration is not long enough to characterize
the full effect of ASP. In addition, the study attempted to
provide accurate deﬁnitions for outcomes and potential
confounders, yet misclassiﬁcation bias may still affect the
results. Finally, it is unclear how changes in antimicrobial
consumption may affect resistance rates and clinical
outcomes.
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